Gubra A/S (GUBRA) - Net Assets
Based on the latest financial reports, Gubra A/S (GUBRA) has net assets worth Dkr1.15 Billion DKK (≈ $179.29 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Dkr1.32 Billion ≈ $206.50 Million USD) and total liabilities (Dkr173.94 Million ≈ $27.21 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See net asset quality index of Gubra A/S to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Dkr1.15 Billion |
| % of Total Assets | 86.82% |
| Annual Growth Rate | 61.84% |
| 5-Year Change | 656.58% |
| 10-Year Change | N/A |
| Growth Volatility | 126.15 |
Gubra A/S - Net Assets Trend (2019–2025)
This chart illustrates how Gubra A/S's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see GUBRA market cap overview.
Annual Net Assets for Gubra A/S (2019–2025)
The table below shows the annual net assets of Gubra A/S from 2019 to 2025. Also explore Gubra A/S (GUBRA) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr1.15 Billion ≈ $179.29 Million |
+154.33% |
| 2024-12-31 | Dkr450.57 Million ≈ $70.50 Million |
-6.06% |
| 2023-12-31 | Dkr479.66 Million ≈ $75.05 Million |
+343.28% |
| 2022-12-31 | Dkr108.21 Million ≈ $16.93 Million |
-28.56% |
| 2021-12-31 | Dkr151.46 Million ≈ $23.70 Million |
+89.31% |
| 2020-12-31 | Dkr80.01 Million ≈ $12.52 Million |
+25.55% |
| 2019-12-31 | Dkr63.73 Million ≈ $9.97 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Gubra A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1676.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Dkr1.13 Billion | 98.57% |
| Common Stock | Dkr16.35 Million | 1.43% |
| Total Equity | Dkr1.15 Billion | 100.00% |
Gubra A/S Competitors by Market Cap
The table below lists competitors of Gubra A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
South Plains Financial Inc
NASDAQ:SPFI
|
$777.89 Million |
|
Rainbow Department Store Co Ltd
SHE:002419
|
$778.23 Million |
|
Luoxin Pharmaceuticals Group Stock Co Ltd
SHE:002793
|
$778.24 Million |
|
TMK
KLSE:5330
|
$778.31 Million |
|
SERVICE STREAM LTD
F:UFY
|
$777.83 Million |
|
RTW Venture Fund Ltd
LSE:RTW
|
$777.76 Million |
|
Celebi Hava Servisi AS
IS:CLEBI
|
$777.74 Million |
|
Glencore PLC
LSE:GLEN
|
$777.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gubra A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 450,573,000 to 1,145,933,000, a change of 695,360,000 (154.3%).
- Net income of 1,690,566,000 contributed positively to equity growth.
- Dividend payments of 1,000,262,000 reduced retained earnings.
- Share repurchases of 4,323,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Dkr1.69 Billion | +147.53% |
| Dividends Paid | Dkr1.00 Billion | -87.29% |
| Share Repurchases | Dkr4.32 Million | -0.38% |
| Other Changes | Dkr9.38 Million | +0.82% |
| Total Change | Dkr- | 154.33% |
Book Value vs Market Value Analysis
This analysis compares Gubra A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 62.08x to 4.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Dkr4.90 | Dkr304.40 | x |
| 2021-12-31 | Dkr9.28 | Dkr304.40 | x |
| 2022-12-31 | Dkr6.63 | Dkr304.40 | x |
| 2023-12-31 | Dkr31.62 | Dkr304.40 | x |
| 2024-12-31 | Dkr27.64 | Dkr304.40 | x |
| 2025-12-31 | Dkr69.61 | Dkr304.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gubra A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 147.53%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 64.11%
- • Asset Turnover: 2.00x
- • Equity Multiplier: 1.15x
- Recent ROE (147.53%) is above the historical average (32.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 15.86% | 7.37% | 0.88x | 2.44x | Dkr4.69 Million |
| 2021 | 44.85% | 26.61% | 0.85x | 1.99x | Dkr52.79 Million |
| 2022 | 3.98% | 2.16% | 0.76x | 2.43x | Dkr-6.51 Million |
| 2023 | -9.28% | -21.72% | 0.33x | 1.30x | Dkr-92.49 Million |
| 2024 | -8.10% | -13.73% | 0.43x | 1.36x | Dkr-81.56 Million |
| 2025 | 147.53% | 64.11% | 2.00x | 1.15x | Dkr1.58 Billion |
Industry Comparison
This section compares Gubra A/S's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $954,924,400
- Average return on equity (ROE) among peers: -39.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gubra A/S (GUBRA) | Dkr1.15 Billion | 15.86% | 0.15x | $777.87 Million |
| ALK-Abelló A/S (ALK-B) | $3.29 Billion | -4.80% | 0.51x | $6.33 Billion |
| Bavarian Nordic (BAVA) | $62.33 Million | 0.00% | 0.34x | $2.56 Billion |
| Genmab A/S (GMAB) | $1.12 Billion | -38.37% | 0.22x | $21.96 Billion |
| Pharma Equity Group A/S Cl A (PEG) | $25.33 Million | -97.14% | 1.67x | $14.33 Million |
| Zealand Pharma A/S (ZEAL) | $278.19 Million | -55.32% | 1.50x | $3.10 Billion |
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for th… Read more